ClearPoint Neuro, Inc. (NASDAQ:CLPT) Shares Bought by D. E. Shaw & Co. Inc.

D. E. Shaw & Co. Inc. increased its stake in ClearPoint Neuro, Inc. (NASDAQ:CLPT - Free Report) by 27.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 288,409 shares of the company's stock after buying an additional 62,889 shares during the quarter. D. E. Shaw & Co. Inc. owned about 1.05% of ClearPoint Neuro worth $4,436,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of CLPT. R Squared Ltd acquired a new stake in shares of ClearPoint Neuro in the fourth quarter valued at about $32,000. Barclays PLC grew its stake in shares of ClearPoint Neuro by 24.3% in the third quarter. Barclays PLC now owns 5,674 shares of the company's stock valued at $64,000 after buying an additional 1,109 shares in the last quarter. AlphaQuest LLC acquired a new stake in shares of ClearPoint Neuro in the fourth quarter valued at about $80,000. Tower Research Capital LLC TRC acquired a new stake in shares of ClearPoint Neuro in the fourth quarter valued at about $93,000. Finally, JPMorgan Chase & Co. grew its stake in shares of ClearPoint Neuro by 58.7% in the third quarter. JPMorgan Chase & Co. now owns 9,770 shares of the company's stock valued at $110,000 after buying an additional 3,612 shares in the last quarter. Institutional investors and hedge funds own 30.08% of the company's stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on CLPT. Stifel Nicolaus increased their target price on ClearPoint Neuro from $19.00 to $25.00 and gave the company a "buy" rating in a research note on Tuesday, April 1st. Wall Street Zen lowered ClearPoint Neuro from a "hold" rating to a "sell" rating in a research note on Thursday. Finally, B. Riley raised their price objective on ClearPoint Neuro from $15.00 to $20.00 and gave the company a "buy" rating in a research note on Tuesday, January 28th.

ClearPoint Neuro Trading Down 1.6%

NASDAQ CLPT traded down $0.19 during mid-day trading on Friday, reaching $11.89. 172,203 shares of the company's stock traded hands, compared to its average volume of 235,726. ClearPoint Neuro, Inc. has a 1-year low of $5.11 and a 1-year high of $19.22. The company has a fifty day simple moving average of $12.80 and a 200-day simple moving average of $14.21. The company has a market cap of $332.79 million, a price-to-earnings ratio of -17.23 and a beta of 1.03.

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.07). The business had revenue of $8.49 million for the quarter, compared to analyst estimates of $8.21 million. ClearPoint Neuro had a negative net margin of 59.64% and a negative return on equity of 62.10%. Equities research analysts forecast that ClearPoint Neuro, Inc. will post -0.66 earnings per share for the current fiscal year.

ClearPoint Neuro Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.